ROLE OF NEUREGULINS AND HEPATOCYTE GROWTH FACTOR IN THE DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER
Abstract
The development of castration-resistant prostate cancer is an important problem of modern oncology. The review is focused on the system of growth factors – neuregulins and hepatocyte growth factor (HGF), direct pathligands of ErbB tyrosine protein kinases and hepatocyte growth factor receptor, c-Met, the activation of which triggers a cascade of signaling pathways, ending by the stimulation of proliferation of cancer cells, their migration under conditions of the development of tolerance to the treatment of castration.
About the Authors
L. V. Spirina
Tomsk Cancer research Institute;
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
Spirina Lyudmila Viktorovna, MD, DSc, Senior Researcher, Laboratory of Tumor Biochemistry, Tomsk Cancer Research Center.
Phone: +7 (3822) 51-45-98. E-mail: spirinalv@oncology.tomsk.ru. SPIN-code: 1336-8363
E. A. Usynin
Tomsk Cancer research Institute
Russian Federation
Russian Federation
Usynin Evgeny Anatolyevich, Md, PhD, Researcher, General Oncology Department.
Phone: +7 (3822) 41-80-92. E-mail: gusi@list.ru. SPIN-code: 1804-0292 .
E. M. Slonimskaya
Tomsk Cancer research Institute;
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
Slonimskaya Elena Mikhailovna, MD, DSC, Professor, Head of General Oncology Department, Tomsk Cancer Research Institute.
Phone: +7 (3822) 41-80-92. E-mail: slonimskaya@rambler.ru. SPIN-code: 7763-6417
I. V. Kondakova
Tomsk Cancer research Institute
Russian Federation
Russian Federation
Kondakova Irina Viktorovna, Tumor Biochemistry.
Phone: +7 (3822) 51- 25-29. E-mail: kondakova@oncology.tomsk.ru. SPIN-code: 9338-4149
A. K. Gorbunov
Tomsk Cancer research Institute
Russian Federation
Russian Federation
Gorbunov Alexey Konstantinovich, intern, Tomsk Cancer Research Center.
E-mail: goorbunov@gmail.com. SPIN-code: 3590-3479
References
1. Spirina L.V., Kondakova I.V., Usynin Y.A., Kolomiets L.A., Choinzonov E.L., Mukhamedov M.R., Chernyshova A.L., Sharova N.P. Proteasome activity in cancer tissues // Sibirskiy onkologicheskiy zhurnal. 2009. № 5. P. 49–52. [in Russian]
2. Ancot F., Leroy C., Muharram G., Lefebvre J., Vicogne J., Lemiere A., Kherrouche Z., Foveau B., Pourtier A., Melnyk O., Giordano S., Chotteau-Lelievre A., Tulasne D. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway // Traffic. 2012. Vol. 13 (9). P. 1261–1272. doi: 10.1111/j.1600-0854.2012.01384.x
3. Bachleitner-Hofmann T., Sun M.Y., Chen C.T., Tang L., Song L., Zeng Z., Shah M., Christensen J.G., Rosen N., Solit D.B., Weiser M.R. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells // Mol. Cancer Ther. 2008. Vol. 7 (11). P. 3499–3508. doi: 10.1158/1535-7163.MCT-08-0374.
4. Barnes C.J., Li F., Talukder A.H., Kumar R. Growth factor regulation of a 26S proteasomal subunit in breast cancer // Clin. Cancer Res. 2005. Vol. 11 (8). P. 2868–2874.
5. Basilico C., Arnesano A., Galluzzo M., Comoglio P.M., Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulinlike region of Met // J. Biol. Chem. 2008. Vol. 283. P. 21267–21277.
6. Carrion-Salip D., Panosa C., Menendez J.A., Puig T., Oliveras G., Pandiella A., De Llorens R., Massaguer A. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands // Int. J. Oncol. 2012. Vol. 41 (3). P. 1128–1138. doi: 10.3892/ijo.2012.1509.
7. Chang H., Riese D.J., Gilbert W., Stern D.E., McMahan U.J. Ligands for ErbB-family receptors encoded by a neuregulin-like gene // Nature. 1997. Vol. 387. P. 509–512.
8. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience // Nat. Rev. Drug Discov. 2008. Vol. 7. P. 504–516.
9. Cruz J.J., Ocana A., Del Barco E., Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer // Ann. Oncol. 2007. Vol. 18. P. 421–430.
10. Garcia-Guzman M., Dolfi F., Zeh K., Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 - Crk signaling complex formation // Oncogene. 1999. Vol. 1. P. 7775–7786.
11. Grimsley S.J., Shini S., Underwood M.A., Edwards J. Heregulin expression and prognosis in prostate adenocarcinoma // Urol. Int. 2011. Vol. 87 (3). P. 363–368. doi: 10.1159/000328627.
12. Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-alpha family of mitogens // Growth Factors. 1994. Vol. 11. P. 235–257.
13. Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase // Oncogene. 1999. Vol. 18. P. 2681–2689.
14. Humphrey P.A., Halabi S., Picus J., Sanford B., Vogelzang N.J., Small E.J., Kantoff P.W. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480 // Clin. Genitourin. Cancer. 2006. Vol. 4. P. 269–274.
15. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors // Nat. Rev. Cancer. 2005. Vol. 5. P. 341–354.
16. Jefferd M., Taylir M., Weidner K.M., Omura S., Vande Wiude G.F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway // Mol. Cell Biol. 1997. Vol. 17 (2). P. 799–808.
17. Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells // J. Biol. Chem. 2000. Vol. 275. P. 8806–8811.
18. Kehinde E.O., Maghrebi M.A., Anim J.T. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers // Can. J. Urol. 2008. Vol. 15 (2). P. 3967–3974.
19. Knudsen B.S., Edlund M. Prostate cancer and the met hepatocyte growth factor receptor // Adv. Cancer Res. 2004. Vol. 91. P. 31–67.
20. Lai A.Z., Abella J.V., Park M. Crosstalk in Met receptor oncogenesis // Trends Cell Biol. 2009. Vol. 19 (10). P. 542–551. doi: 10.1016/j. tcb.2009.07.002.
21. Lee R.J., Smith M.R. Targeting MET and VEGFR Signaling in Castration- Resistant Prostate Cancer // Cancer J. 2013. Vol. 19 (1). P. 90–98.
22. Li C., Ma J., Zhao H., Blagg B.S., Dobrowsky R.T. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun // ASN Neuro. 2012. Vol. 4 (7). P. 425–437. doi: 10.1042/20120047.
23. Li J.X., Fei X.M., Lu H., Hu H.J., Li J.Y. Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients // Zhongguo Shi Yan Xue Ye Za Zhi. 2011. Vol. 19 (5). P. 1204–1208.
24. Magnifico A., Tagliabue E., Ardini E., Casalini P., Colnaghi M.I., Menaed S. Heregulin beta1 induces the down regulation and the ubiquitinproteasome degradation pathway of p185HER2 oncoprotein // FEBS Lett. 1998. Vol. 422 (2). P. 129–131.
25. Montero J.C., Rodriguez-Barrueco R., Ocana A., Diaz-Rodriguez E., Wsparis-Ogando A., Pandiella A. Neuregulins and cancer // Clin. Cancer Res. 2008. Vol. 14 (11). P. 3237–3241.
26. Naughton M., Picus J., Zhu X., Catalona W.J., Vollmer R.T., Humphrey P.A. Scatter factor-hepatocyte growh factor elevation in the serum of patients with prostate cancer // J. Urol. 2001. Vol. 165. P. 1325–1328.
27. Paumelle R., Tulasne D., Kherrouche Z., Plaza S., Leroy C., Reveneau S., Vandenbunder B., Fafeur V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway // Oncogene. 2002. Vol. 21. P. 2309–2319.
28. Pfeil K., Edel I.E., Putz T., Ramonet R., Culig Z., Ueberall F., Bartsch G., Klocker H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells // Prostate. 2004. Vol. 58 (3). P. 259–268.
29. Pignon J.C., Koopmansch B., Nolens G., Delacroix L., Waltregny D., Winkler R. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines // Cancer Res. 2009. Vol. 69 (7). P. 2941–2949. doi: 10.1158/0008-5472.CAN-08-3760.
30. Ryan C.J., Rosenthal M., Ng S., Alumkal J., Picus G., Gravis G., Fizazi K., Forget F., Machiels J.P., Srinivas S., Zhu M., Nabg R., Oliner K.S., Jiang Y., Loh E., Dubey S., Gerritsen W.R. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone // Clin. Cancer Res. 2013. Vol. 19 (1). P. 215–224. doi: 10.1158/1078-0432.CCR-12-2605.
31. Schmukler E., Shai B., Ehrlich M., Pinkas-Kramarski R. Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition // PloS One. 2012. Vol. 7 (5). e36828. doi: 10.1371/journal.pone.0036828.
32. Shimizu H., Seiki T., Asada M., Yoshimatsu K., Koyama N. Alpha6- beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells // Oncogene. 2003. Vol. 22 (6). P. 831–839.
33. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene // Science. 1987. Vol. 235. P. 177–182.
34. Syed Z.A., Yin W., Hughes K., Gill J.N., Shi R., Clifford J.L. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop // BMC Cancer. 2011. Vol. 11. P. 180. doi: 10.1186/1471-2407-11-180.
35. Tinz M., Chtn B., Chqn S.Y., Semenas J., Abrahamson P.A., Diveyi N. Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer // Plos One. 2013. Vol. 8 (11). e79573. doi: 10.1371/journal.pone.0079573.
36. Tu W.H., Zhu C., Clark C., Christensen J.C., Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer // BMC Cancer. 2010. Vol. 10. P. 556. doi: 10.1186/1471-2407-10-556.
37. Wicha M.S. B4 androgen ablation: attacking the prostate cancer stem cell // J. Clin. Invest. 2013. Vol. 123 (2). P. 563–565. doi: 10.1172/ JCI67460.
38. Xiao G.H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G.F., Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/ Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways // Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. P. 247–252.
39. Yeh C.Y., Shin S.M., Yeh H.H., Wu T.J., Shin J.W., Chang T.Y. [et al.]. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer // BMC Cancer. 2011. Vol. 11. P. 139. doi: 10.1186/1471-2407-11-139.
40. Yonezawa M., Wada K., Tatsuguchi A., Akamatsu A., Gudis K., Seo T., Mitsui K., Nagata K., Tanaka S., Fujimori S., Sakamoto C. Heregulin-induced VEGF expression via the ErbB3 signaling pathligands way in colon cancer // Digestion. 2009. Vol. 80 (4). P. 215–225. doi: 10.1159/000229775.
41. Yu H., Li X., Sun S., Gao X., Zhou D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation // Biochem. Biophys. Res. Commun. 2012. Vol. 427 (3). P. 659–665. doi: 10.1016/j.bbrc.2012.09.117.
42. Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Jillan K., Crowley C., Brush J., Godowski P.J. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4 // PNAS (USA). 1997. Vol. 94 (18). P. 9562–9567.
43. Zhou H., Zhang Y., Hamburger A.W. EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells // Anticancer Res. 2011. Vol. 31 (10). P. 3129–3135.
Review
For citations:
Spirina L.V., Usynin E.A., Slonimskaya E.M., Kondakova I.V., Gorbunov A.K. ROLE OF NEUREGULINS AND HEPATOCYTE GROWTH FACTOR IN THE DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER. Siberian journal of oncology. 2015;1(4):80-86. (In Russ.)
Views:
588
Email this article 
